Rupatadine
| Rupatadine
| |
| Systematic (IUPAC) name | |
| 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridyl)methyl)- 4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine | |
| Identifiers | |
| CAS number | |
| ATC code | R06 |
| PubChem | |
| Chemical data | |
| Formula | C26H26ClN3 |
| Mol. mass | 415.958 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 99% |
| Metabolism | Hepatic, CYP-mediated |
| Half life | 5.9 hours |
| Excretion | Fecal (60.9%) and renal (34.6%) |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Overview
Rupatadine is a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Ruptatadine is marketed by Panacea-Biotech under the trade name Ralif. Ralif is approved for the treatment of allergic rhinitis.
External links
Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added
Pictures
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies